Kathleen D. Scott - Net Worth and Insider Trading

Kathleen D. Scott Net Worth

The estimated net worth of Kathleen D. Scott is at least $197,853 dollars as of 2024-11-05. Kathleen D. Scott is the CFO of ARS Pharmaceuticals Inc and owns about 13,199 shares of ARS Pharmaceuticals Inc (SPRY) stock worth over $197,853. Details can be seen in Kathleen D. Scott's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kathleen D. Scott has not made any transactions after 2024-10-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Kathleen D. Scott

Kathleen D. Scott Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kathleen D. Scott owns 5 companies in total, including Histogen Inc (HSTO) , Dermata Therapeutics Inc (DRMA) , and Silverback Therapeutics Inc (SBTX) among others .

Click here to see the complete history of Kathleen D. Scott’s form 4 insider trades.

Insider Ownership Summary of Kathleen D. Scott

Ticker	Comapny	Transaction Date	Type of Owner
HSTO	Histogen Inc	2019-11-18	director
DRMA	Dermata Therapeutics Inc	2021-08-12	director
SBTX	Silverback Therapeutics Inc	2022-11-08	Chief Financial Officer
		2024-10-16	Chief Financial Officer
		2023-09-29	director

Kathleen D. Scott Latest Holdings Summary

Kathleen D. Scott currently owns a total of 1 stock. Kathleen D. Scott owns 13,199 shares of ARS Pharmaceuticals Inc (SPRY) as of October 16, 2024, with a value of $197,853.

Latest Holdings of Kathleen D. Scott

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SPRY	ARS Pharmaceuticals Inc	2024-10-16	13,199	14.99	197,853

Holding Weightings of Kathleen D. Scott

Kathleen D. Scott Form 4 Trading Tracker

According to the SEC Form 4 filings, Kathleen D. Scott has made a total of 3 transactions in ARS Pharmaceuticals Inc (SPRY) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in ARS Pharmaceuticals Inc is the sale of 12,500 shares on October 16, 2024, which brought Kathleen D. Scott around $200,000.

Insider Trading History of Kathleen D. Scott

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kathleen D. Scott Trading Performance

GuruFocus tracks the stock performance after each of Kathleen D. Scott's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kathleen D. Scott is 50.17%. GuruFocus also compares Kathleen D. Scott's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kathleen D. Scott within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kathleen D. Scott's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kathleen D. Scott

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	40.73
Relative Return to S&P 500(%)	43.47

Kathleen D. Scott Ownership Network

Ownership Network List of Kathleen D. Scott

No Data

Ownership Network Relation of Kathleen D. Scott

Kathleen D. Scott Owned Company Details

What does Histogen Inc do?

Who are the key executives at Histogen Inc?

Kathleen D. Scott is the director of Histogen Inc. Other key executives at Histogen Inc include See Remarks Joyce Reyes , director & See Remarks Richard W Pascoe , and See Remarks Moya Daniels .

Histogen Inc (HSTO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Histogen Inc (HSTO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Histogen Inc (HSTO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Histogen Inc (HSTO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Histogen Inc Insider Transactions

No Available Data

What does Dermata Therapeutics Inc do?

Who are the key executives at Dermata Therapeutics Inc?

Kathleen D. Scott is the director of Dermata Therapeutics Inc. Other key executives at Dermata Therapeutics Inc include 10 percent owner & Pres. & CEO and Chairman Gerald T Proehl , Chief Financial Officer Van Hoose Kyri K. , and Chief Financial Officer Thomas Insley .

Dermata Therapeutics Inc (DRMA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dermata Therapeutics Inc (DRMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dermata Therapeutics Inc (DRMA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dermata Therapeutics Inc (DRMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dermata Therapeutics Inc Insider Transactions

No Available Data

What does Silverback Therapeutics Inc do?

Who are the key executives at Silverback Therapeutics Inc?

Kathleen D. Scott is the Chief Financial Officer of Silverback Therapeutics Inc. Other key executives at Silverback Therapeutics Inc include Chief Operating Officer Brian Dorsey , Chief Legal Officer Alexander A Fitzpatrick , and director & 10 percent owner & other: * Director by deputization Deerfield Management Company, L.p. (series C) .

Silverback Therapeutics Inc (SBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Silverback Therapeutics Inc (SBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Silverback Therapeutics Inc (SBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Silverback Therapeutics Inc (SBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Silverback Therapeutics Inc Insider Transactions

No Available Data

What does ARS Pharmaceuticals Inc do?

Who are the key executives at ARS Pharmaceuticals Inc?

Kathleen D. Scott is the Chief Financial Officer of ARS Pharmaceuticals Inc. Other key executives at ARS Pharmaceuticals Inc include 10 percent owner & Chief Medical Officer Sarina Tanimoto , director & 10 percent owner & President and CEO Richard E Lowenthal , and Chief Commercial Officer Eric Karas .

ARS Pharmaceuticals Inc (SPRY) Insider Trades Summary

Over the past 18 months, Kathleen D. Scott made 2 insider transaction in ARS Pharmaceuticals Inc (SPRY) with a net sale of 25,000. Other recent insider transactions involving ARS Pharmaceuticals Inc (SPRY) include a net sale of 1,603,260 shares made by Sarina Tanimoto , a net sale of 1,603,260 shares made by Richard E Lowenthal , and a net sale of 543,896 shares made by Laura Shawver .

In summary, during the past 3 months, insiders sold 3,229,754 shares of ARS Pharmaceuticals Inc (SPRY) in total and bought 0 shares, with a net sale of 3,229,754 shares. During the past 18 months, 5,780,170 shares of ARS Pharmaceuticals Inc (SPRY) were sold and 8,937,557 shares were bought by its insiders, resulting in a net purchase of 3,157,387 shares.

ARS Pharmaceuticals Inc (SPRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARS Pharmaceuticals Inc Insider Transactions

No Available Data

What does Graf Acquisition Corp IV do?

Who are the key executives at Graf Acquisition Corp IV?

Kathleen D. Scott is the director of Graf Acquisition Corp IV. Other key executives at Graf Acquisition Corp IV include Chief Operating Officer Pierre Gagnon , director & 10 percent owner & other: See Remarks Sangwoo Park , and CSO and CIO Yong Man Kim .

Graf Acquisition Corp IV (GFOR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Graf Acquisition Corp IV (GFOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Graf Acquisition Corp IV (GFOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Graf Acquisition Corp IV (GFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Graf Acquisition Corp IV Insider Transactions

No Available Data

Kathleen D. Scott Mailing Address

Above is the net worth, insider trading, and ownership report for Kathleen D. Scott. You might contact Kathleen D. Scott via mailing address: C/o Conatus Pharmaceuticals Inc., 16745 West Bernardo Drive, Suite 200, San Diego Ca 92127.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.